Skip to main content
. Author manuscript; available in PMC: 2014 Mar 28.
Published in final edited form as: Cell Stem Cell. 2013 Jan 17;12(3):316–328. doi: 10.1016/j.stem.2012.12.011

Figure 6.

Figure 6

see also Figure S7 and Table S6

a) In vivo experimental design used in the present studies. b) Engraftment of BC progenitors in spleen and bone marrow following vehicle (n=27) and sabutoclax treatment (5mg/kg, n=26). Graph shows mean +/− SEM for 3 different BC patient samples and statistical analysis by Mann-Whitney test. c) Representative immunohistochemical analysis of BCL2 and MCL1 staining in engrafted bone marrow following vehicle and sabutoclax treatment. Scale bars equal 100μm. d) Quantification of BCL2+ and MCL1+ cells in the endosteum of engrafted bone marrow following vehicle (n=3) and sabutoclax (n=3) treatment. Graph shows mean +/− SEM. e) FACS-cell cycle analysis of CD45+ bone marrow engrafted BC cells in vehicle (n=6) and sabutoclax (n=5) treated mice. Graph shows mean +/− SEM. *p<0.05 by unpaired t-test.